c-Met inhibitors

被引：18

作者：

Mughal, Anum ^{[1
]}

Aslam, Hafiz Muhammad ^{[1
]}

Sheikh, Asfandyar ^{[1
,2
]}

Khan, Agha Muhammad Hammad ^{[3
]}

Saleem, Shafaq ^{[1
]}

机构：

[1] Dow Univ Hlth Sci, Dow Med Coll, Karachi, Pakistan

[2] Pakistan Res Evolut Students Soc, Karachi, Pakistan

[3] Dow Univ Hlth Sci, Sindh Med Coll, Karachi, Pakistan

来源：

INFECTIOUS AGENTS AND CANCER | 2013年 / 8卷

关键词：

c-Met; Tyrosine kinase; Cancer; HEPATOCYTE GROWTH-FACTOR; FACTOR-RECEPTOR; SOMATIC MUTATIONS; KINASE INHIBITORS; ONCOGENE; IDENTIFICATION; PROTOONCOGENE; DISCOVERY; DOMAIN; GENE;

D O I：

10.1186/1750-9378-8-13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio-or immunotherapy

引用

页数：2

共 50 条

[1] C-MET INHIBITORS
Adjei, A. A.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S22 - S22
[2] c-Met inhibitors
Anum Mughal
Hafiz Muhammad Aslam
Asfandyar Sheikh
Agha Muhammad Hammad Khan
Shafaq Saleem
Infectious Agents and Cancer, 8
[3] Isothiocyanatostilbenes as novel c-Met inhibitors
Gray, Alana L.
Coleman, David T.
Castore, Reneau F.
Mohyeldin, Mohamed M.
El Sayed, Khalid A.
Cardelli, James A.
ONCOTARGET, 2015, 6 (38) : 41180 - 41193
[4] Development of c-MET pathway inhibitors
Liu, Xiangdong
Newton, Robert C.
Scherle, Peggy A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (09) : 1225 - 1241
[5] Isothiocyanatostilbenes as novel c-Met inhibitors
Gray, A. L.
Coleman, D. T.
Castore, R. F.
Mohyeldin, M. M.
El Sayed, K. A.
Cardelli, J. A.
MOLECULAR BIOLOGY OF THE CELL, 2015, 26
[6] Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met
Zaky, Mohamed Y.
Liu, Xiuxiu
Wang, Taishu
Wang, Shanshan
Liu, Fang
Wang, Duchuang
Wu, Yueguang
Zhang, Yang
Guo, Dong
Sun, Qianhui
Li, Qiong
Zhang, Jinrui
Zhang, Yingqiu
Dong, Weijie
Liu, Zhenhua
Liu, Shuyan
Liu, Han
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 680
[7] c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors.
Jardim, Denis Leonardo Fontes
Gagliato, Debora De Melo
Falchook, Gerald Steven
Wheler, Jennifer J.
Zinner, Ralph
Janku, Filip
Subbiah, Vivek
Piha-Paul, Sarina Anne
Fu, Siqing
Tannir, Nizar M.
Corn, Paul Gettys
Tang, Chad
Hess, Kenneth R.
Roy-Chowdhuri, Sinchita
Kurzrock, Razelle
Meric-Bernstam, Funda
Hong, David S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[8] Synthesis of triazolotriazine derivatives as c-Met inhibitors
Yuting Guo
Xia Peng
Yinchun Ji
Yitong Zhang
Jian Ding
Zhengsheng Zhan
Jing Ai
Wenhu Duan
Molecular Diversity, 2021, 25 : 839 - 846
[9] c-MET Inhibitors in the Treatment of Lung Cancer
Gozdzik-Spychalska, Joanna
Szyszka-Barth, Katarzyna
Spychalski, Lukasz
Ramlau, Katarzyna
Wojtowicz, Jerzy
Batura-Gabryel, Halina
Ramlau, Rodryg
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (04) : 670 - 682
[10] Synthesis and SAR of diaminopyrimidines as c-Met inhibitors
Weinberg, Linda R.
Albom, Mark S.
Angeles, Thelma S.
Diebold, James L.
Husten, Jean
Lisko, Joseph G.
Milkiewicz, Karen L.
Murthy, Seetha
Ott, Gregory R.
Ruggeri, Bruce A.
Theroff, Jay P.
Underiner, Ted L.
Dorsey, Bruce D.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240

← 1 2 3 4 5 →